Clinical Trial

Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Project Name Clinical Research Protocol on Accelerating Motor Rehabilitation in Postoperative Motor-Deficient Glioma Patients Using nrTMS Research Objectives 1. Investigate the relationship between motor rehabilitation and changes in motor functional networks after nrTMS therapy, and confirm the contralateral hand motor area as an effective rehabilitation target. 2. Validate the efficacy of high-frequency nrTMS stimulation in rehabilitating motor deficits in glioma patients. Study Design \> A randomized, double-blind, sham-controlled clinical trial. Eligible postoperative glioma patients with motor dysfunction will be randomized into nrTMS treatment or sham groups. High-frequency nrTMS or sham stimulation targeting the contralateral hand motor area will be administered for 7 consecutive days. Fugl-Meyer Assessment (FMA) scores and muscle strength of the affected limb will be evaluated to determine the superiority of nrTMS over sham stimulation. Total Cases The study comprises two parts, each enrolling 43 patients. Case Selection Inclusion Criteria: A. Right-handed; B. Age: 25-65 years; C. No prior neurological disease history; D. Awake craniotomy with intraoperative direct cortical stimulation or MEP mapping for motor area localization; E. Postoperative pathology confirms newly diagnosed glioma; F. Willing to undergo nrTMS therapy; G. Persistent motor dysfunction (muscle strength/FMA score not restored to preoperative levels) at postoperative day 7. Exclusion Criteria: A. Tumor crossing midline to the contralateral hemisphere; B. Head motion \>1 mm or rotation \>1° during rs-fMRI acquisition; C. Absence of postoperative motor or speech dysfunction; D. Vulnerable populations (e.g., pregnant women). Treatment Protocol High-frequency nrTMS stimulation targeting the contralateral hand motor area (thumb region). Efficacy Evaluation Primary Outcome: Muscle strength recovery rate of the affected limb. Secondary Outcome: FMA score recovery rate. Safety Evaluation: Pre- and post-treatment MRI to monitor intracranial changes. Statistical Methods (1) Randomization into nrTMS and sham groups. (2) Baseline comparisons using t-tests and chi-square tests. (3) Longitudinal analysis of muscle strength (chi-square) and FMA scores (t-tests) at key timepoints: preoperative, pretreatment, post-treatment, 1/2/3 months postoperatively.
Trial Details
NCT Number NCT07285525
Lead Sponsor Beijing Neurosurgical Institute
Conditions Glioma
Enrollment 43 participants
Start Date 2025-04-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-16